These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand? Correale M; Ferraretti A; Monaco I; Grazioli D; Di Biase M; Brunetti ND Vasc Health Risk Manag; 2018; 14():253-264. PubMed ID: 30323613 [TBL] [Abstract][Full Text] [Related]
3. Toward Precision Medicine in Pulmonary Arterial Hypertension. Austin ED; Loyd JE Am J Respir Crit Care Med; 2015 Dec; 192(11):1272-4. PubMed ID: 26623685 [No Abstract] [Full Text] [Related]
4. The importance of sex in pulmonary hypertension. Rich S Chest; 2012 Jan; 141(1):4-5. PubMed ID: 22215821 [No Abstract] [Full Text] [Related]
5. Macitentan for the treatment of pulmonary arterial hypertension. DuBrock HM; Channick RN Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329 [TBL] [Abstract][Full Text] [Related]
6. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Langleben D Clin Chest Med; 2007 Mar; 28(1):117-25, viii. PubMed ID: 17338931 [TBL] [Abstract][Full Text] [Related]
7. A Concerning Trend for Patients With Pulmonary Hypertension in the Era of Evidence-Based Medicine. Maron BA; Ryan JJ Circulation; 2019 Apr; 139(16):1861-1864. PubMed ID: 30986105 [No Abstract] [Full Text] [Related]
8. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension. Miyagawa K; Emoto N Ther Adv Cardiovasc Dis; 2014 Oct; 8(5):202-16. PubMed ID: 24990369 [TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension. Chaumais MC; Guignabert C; Savale L; Jaïs X; Boucly A; Montani D; Simonneau G; Humbert M; Sitbon O Am J Cardiovasc Drugs; 2015 Feb; 15(1):13-26. PubMed ID: 25421754 [TBL] [Abstract][Full Text] [Related]
11. [Pulmonary arterial hypertension. Therapy with the endothelin-1 receptor antagonist bosentan]. Musch A Med Monatsschr Pharm; 2006 Jul; 29(7):242-5. PubMed ID: 16866076 [TBL] [Abstract][Full Text] [Related]
12. [Blockade of endothelin receptor with bosentan--a new principle of treatment in pulmonary arterial hypertension]. Nielsen-Kudsk JE Ugeskr Laeger; 2003 Jul; 165(29):2891-4. PubMed ID: 12908360 [TBL] [Abstract][Full Text] [Related]
13. Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration. Burger CD Ann Am Thorac Soc; 2015 Jun; 12(6):959. PubMed ID: 26075561 [No Abstract] [Full Text] [Related]
14. Reply: Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration. Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I Ann Am Thorac Soc; 2015 Jun; 12(6):960. PubMed ID: 26075562 [No Abstract] [Full Text] [Related]
15. Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. Benza RL; Gomberg-Maitland M; Demarco T; Frost AE; Torbicki A; Langleben D; Pulido T; Correa-Jaque P; Passineau MJ; Wiener HW; Tamari M; Hirota T; Kubo M; Tiwari HK Am J Respir Crit Care Med; 2015 Dec; 192(11):1345-54. PubMed ID: 26252367 [TBL] [Abstract][Full Text] [Related]
16. [Endothelin-receptor antagonists in therapy of pulmonary arterial hypertension]. Ghofrani HA Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S177-8. PubMed ID: 19718611 [No Abstract] [Full Text] [Related]